EU's CHMP recommends Merck & Co's Sycrest for bipolar but not schizophrenia
This article was originally published in Scrip
Executive Summary
The EU's CHMP has endorsed the approval of Merck & Co's Sycrest (asenapine) 5mg and 10mg sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults, but has rejected an indication for schizophrenia.